GDUFA: How Much Does FDA Know About U.S. Generic Market After Facility Self-Identification?
This article was originally published in The Gold Sheet
Executive Summary
FDA continues to analyze facility data following generic drug facility fee announcement; some fees were higher than anticipated after fewer manufacturing plants registered than expected. But industry believes the count is accurate and illustrates the influence of foreign manufacturers.